Back to today’s briefing

Story perspectives

BluMaiden Biosciences Appoints New Leadership, Targets Inflammation

2/20/2025

50 5

Summary

Story summary

BluMaiden Biosciences, an innovative AI drug discovery company from Singapore, has appointed Dr. Terence Kelly as interim CEO and Professor Damian O’Connell as Chair of the Science Advisory Board. With a mission to create safer therapeutics from human-derived small molecules, BluMaiden is set to propel three inflammatory disease targets into pre-clinical models while forging new commercial partnerships.

1 of 1

Story summary

BluMaiden Biosciences, an innovative AI drug discovery company from Singapore, has appointed Dr. Terence Kelly as interim CEO and Professor Damian O’Connell as Chair of the Science Advisory Board. With a mission to create safer therapeutics from human-derived small molecules, BluMaiden is set to propel three inflammatory disease targets into pre-clinical models while forging new commercial partnerships.